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Background: Numerous studies have yielded inconclusive results regarding the relationship between anti-apoptotic
protein Bcl-2 expression and the sensitivity to chemotherapy in the patients with breast cancer. The purpose of the
current study was therefore to elaborate their relationship.
Methods, findings: A total of 23 previously published eligible studies involving 2,467 cases were identified and
included in this meta-analysis. Negative Bcl-2 expression was associated with good chemotherapy response in breast
cancer patients (total objective response [OR]: risk ratio [RR] = 1.16, 95% confidence interval [CI] = 1.02-1.32, p = 0.026;
total complete response [CR]: RR = 1.67, 95% CI = 1.24-2.24, p = 0.001; pathological CR: RR = 1.92, 95% CI = 1.38-2.69, p <
0.001). In further stratified analyses, this association remained for sub-groups of response in neoadjuvant chemotherapy
setting, especially pathological CR. Besides, negative Bcl-2 expression was significantly associated with good OR and
pathological CR in anthracycline-based chemotherapy subgroup. Furthermore, there were significant links between
negative Bcl-2 expression and taxane-based chemotherapy with pathological CR, but not OR.
Conclusion: The results of the present meta-analysis suggest that Bcl-2 expression is a predictive factor for
chemotherapy sensitivity in breast cancer patients. They could also potentially benefit further clinical treatment for
breast cancers.
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Breast cancer remains a major medical problem in women
despite of dramatic advances in clinical and research have
been achieved in the last three decades. Chemotherapies
including neoadjuvant chemotherapy, adjuvant chemo-
therapy, and systemic chemotherapy, are widely used in
breast cancer treatment. However, whether a patient re-
sponds to chemotherapy remains unpredictable, a propor-
tion of patients fail to respond to chemotherapy, or even
progress during therapy. Because the information on the
drug sensitivity of tumors is often unknown before treat-
ment initiation, many patients are treated, but only a few
are benefited. Thus, predicting how well a patient will* Correspondence: liucy@wuxiph.com; lphty1_1@163.com
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stated.respond to chemotherapy and the risk of relapse is essen-
tial in deciding the best treatment option for each individ-
ual patient. Multiple biomarkers with potential predictive
value have been evaluated in breast cancer, which may be
useful for identifying those patients who would benefit
from certain chemotherapy [1].
Conventional chemotherapeutic agents generally kill
via the mitochondrial apoptotic pathway [2]. Mitochon-
drial priming is controlled by the Bcl-2 family of pro-
teins [2,3]. This family consists of both pro-apoptotic
and anti-apoptotic members. If pro-apoptotic members
overwhelm the anti-apoptotic members, the threshold
of death is crossed and the cell dies through apoptosis.
The ability of Bcl-2 to prevent apoptosis is antagonized by
the pro-apoptotic members of the Bcl-2 family [4]. Cyto-
toxic chemo-agents that promote apoptosis through DNA
damage or microtubule disruption can be inhibited byd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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expression of Bcl-2 increased the resistance of MCF-7
cells to doxorubicin, and this resistance was positively
correlated with Bcl-2expression level of individual
MCF/ Bcl-2 clones [6]. Studies demonstrated that Bcl-
2 inhibition through targeted-RNAi knockdown or
Bcl-2 antagonist (ABT-737) increased cellular response
to daunorubicin, etoposide, and mitoxantrone in the
THP-1 and OCI-AML3 cell lines [7], and targeting of
the proteins Bcl-2 and Bcl-xL with ABT-737 may re-
verse the acquired radioresistance of MDA-MB-231R
cells in vitro and in vivo [8].
Although there are now a large number of studies focus-
ing on Bcl-2 expression in breast cancers, however, the as-
sociation between its expression and chemosensitivity was
not conclusive, mostly due to the small sample size of each
study. We therefore performed a meta-analysis of the
value of Bcl-2 expression for predicting sensitivity to
chemotherapy in breast cancer.Figure 1 Improving the quality of reports of meta-analyses of random
(QUOROM) statement flow diagram.Materials and methods
Publication search
PubMed, Embase, and Web of Science databases were
searched (up to September 20, 2013) using the search
terms: ‘Bcl-2’, ‘BCL2’, ‘bcl’, ‘bcl*’, ‘B-cell CLL/lymphoma 2’,
‘chemotherapy’ and ‘breast cancer’. All potentially eligible
studies were retrieved and their bibliographies were care-
fully scanned to identify other eligible studies. Additional
studies were identified by a hand search of the references
cited in the original studies. When multiple studies of the
same patient population were identified, we included the
published report with the largest sample size. Only studies
published in English were included in this meta-analysis.
Inclusion and exclusion criteria
Studies included in this meta-analysis had to meet all of the
following criteria: (a) evaluation of Bcl-2 expression for pre-
dicting the response to chemotherapy in breast cancer, (b)
studies with data on initial treatment, excluding studiesized controlled trials; the Quality of Reporting of Meta-Analyses
Table 1 Characteristics of studies included in the meta-analysis
Author Year Country Case Disease stage Method Treatment Detection Pr ed information
on toff value
Response
Grim [12] 2012 Czech
Republic
61 locally advanced NCT TAC IHC ≥1 stained cell Pathological CR
Chen [13] 2012 China 91 II-IIIC NCT PCb IHC ≥1 stained cell Pathological CR
Petrarca [14] 2011 Brazil 45 II-III NCT AC-T IHC >5 ression score range, 0–15) Pathological CR
von Minckwitz [15] 2008 Germany 196 T2-3(≥3 cm) N0-2 M0 NCT ddAT with or
without tamoxifen
IHC >1 ange 0-3+) Pathological CR
Vargas-Roig [16] 2008 Argentina 110 T2–4 N0–1 M0 NCT FAC/FEC or D/E IHC >3 of stained cells PR + CR
Keam [17] 2007 Korea, 145 II-III NCT docetaxel + doxorubicin IHC ≥1 stained cell OR
Tiezzi [18] 2006 Brazil 44 locally advanced NCT FEC or DE IHC ≥5 ge 0–7) OR
Noguchi [19] 2006 Japan 63 NR NR Docetaxel IHC NR OR






2006 Mexico 40 IIB-IIIB NCT FAC IHC ≥1 stained cell OR
Prisack [22] 2005 Germany 517 locally advanced NCT EC ± RT IHC sco ≥100 Pathological CR
Kim [23] 2005 Japan 63 tumor >3 cm and axillary
lymph node involvement
NCT docetaxel IHC Gr 2 and 3 Pathologic
responders
Buchholz [24] 2005 USA 82 II-IV NCT FAC IHC pre ce of any cytoplasmic
sta g of the tumor cell cytoplasm
Pathological CR
Pusztai [25] 2004 USA 28 IIA-IIIB NCT FAC IHC an nal in neoplastic cells Pathological CR
Ogston [26] 2004 UK 104 large and locally advanced NCT anthracycline-based ±
docetaxel
IHC ≥1 stained cell Good pathological
response
Mathieu [27] 2004 France 129 T2 > 3 cm–T4 NCT AVCMF or FAC/FEC IHC ≥1 stained cell Pathological CR
Stearns [28] 2003 USA 29 T3 or T4 NCT A-T IHC Cy asmic staining.Intensity
an positive cells.
Sco 6 = positive
Pathological CR
Geisler [29] 2001 Norway 94 T3/T4 and/or N2 tumors NCT and first-line EC IHC ind 6 PR
Pernick [30] 2000 USA 34 IIB or III NCT adriamycin (n = 32), taxol
(n = 7), or taxotere (n = 7)
IHC 5% more tumor
cel ained.
CR
Bottini [31] 2000 Italy 157 T2-4 N0-1 M0 NCT CMF ± tamoxifen
or epirubicin











































Table 1 Characteristics of studies included in the meta-analysis (Continued)
Nole [32] 1999 Italy 39 T1-T3 NCT FLN IHC >10% stained cell OR
Colleoni [33] 1999 Italy 73 T2-T3,N0-2 NCT FLN or AC IHC >10% stained cell OR





NCT, neoadjuvant chemotherapy; IHC, immunohistochemistry; A, doxorubicin; E, epirubicin; D, docetaxel; P, paclitaxel; F, 5-fluorouracil; EC, epirubicin and cyclophosphamide; FEC, 5-fluorouracil, epirubicin, and cyclo-
phosphamide; FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide; CMF, cyclophosphamide, mitomycin C and 5-fluorouracil; AVCMF, doxorubicin, vincristine, cyclophosphamide, methotrexate and 5-fluorouracil; P-
FEC, sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide; FUMI regimen, 5-fluorouracil (1,000 mg/m2 on days 1 and 2) and mitomycin; PCb, paclitaxel + carboplatin; RT radiation therapy; ddAT, dose-dense (bi-
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scribed therapeutic response, (d) retrospective or prospect-
ive cohort study, (e) inclusion of sufficient data to allow the
estimation of a risk ratio (RR) with 95% confidence inter-
vals (95% CI), and (f) studies published in English. Letters
to the editor, reviews, and articles published in books, or
papers published in a language other than English were
excluded.
Data extraction and definitions
According to the inclusion criteria listed above, the follow-
ing data were extracted for each study: the first author’s
surname, publication year, country of origin, number of
patients analyzed, types of measurement, and the treat-
ment. Data on the main outcomes were entered in tables
showing the response to chemotherapy with respect to
Bcl-2 expression. Information was carefully and independ-
ently extracted from all eligible publications by two of theFigure 2 Forest plots of RR were assessed for association between Bc
with chemotherapy.authors (Yang and Chen). Any disagreement between the
researchers was resolved by discussions until a consensus
was reached. If they failed to reach a consensus, a third in-
vestigator (Lu) was consulted to resolve the dispute.
Response was defined as complete response (CR), partial
response (PR), or objective response (OR) (OR = CR + PR).
Non-response was defined as stable disease (SD) or pro-
gressive disease (PD), according to WHO criteria [9] or
RECIST (Response Evaluation Criteria in Solid Tumors)
criteria [10].
Statistical analysis
RR with 95% CIs was used to estimate the association
between Bcl-2 expression and response to chemotherapy
in breast cancer patients. Subgroup analyses were per-
formed to evaluate the effects of neoadjuvant chemotherapy
and different treatment regimens (anthracycline-based and
taxane-based). Heterogeneity assumption was checkedl-2 and total OR among breast cancer patients treated
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erogeneity among studies. We also quantified the effect
of heterogeneity using I2 = 100% × (Q - df )/Q. I2 values
of <25% may be considered "low", values of about 50%
may be considered "moderate" and values of >75%
maybe considered "high" [11]. In the absence of statis-
tical heterogeneity, a fixed effects model was employed
(the Mantel–Haenszel method). If heterogeneity was
present, a random effects model (DerSimonian–Laird
method) was used to account for inter-study heterogen-
eity. Funnel plots and the Egger’s test were employed to
estimate the possible publication bias. We also performed
sensitivity analysis by omitting each study or specific stud-
ies to find potential outliers. Statistical analyses were con-
ducted using Stata (version SE/10; StataCorp, College
Station, TX). p values for all comparisons were two-tailed
and statistical significance was defined as p < 0.05 for all
tests, except those for heterogeneity.
Results
Eligible studies
A total of 1,086 articles were retrieved by a literature search
of the PubMed, Embase, and Web of Science databases,
using different combinations of key terms. As indicated in
the search flow diagram (Figure 1), 23 studies reported at
least one of the outcomes of interest and were included in
this meta-analysis [12-34]. The main features of these eli-
gible studies are summarized in Table 1. The sample sizes
in all the eligible studies ranged from 28–517 patients (me-









Pathological CR 10 [12-15,20,22,24,25,27,28]
Response to anthracycline-based
OR 15 [12,14-22,24-29]
Pathological CR 9 [12,14,15,20,22,24,25,27,28
Response to docetaxel-based
OR 8 [12-15,17,19,23,28]
Pathological CR 4 [12-14,28]
N, number of studies; Ph, p value of Q-test for heterogeneity.
*The pooled RR was calculated using a fixed-effects model (the Mantel–Haenszel m
#The pooled RR was calculated using a random-effects model (the DerSimonian an
Subgroup analysis was performed when there were at least two studies in each sub[SD] =107). Overall, the eligible studies included a total of
2,467 patients. Nineteen of the studies were conducted in
European or North American populations with mixed
but mostly white participants (2,105 patients), whereas
four were conducted in East Asian populations (362 pa-
tients).Data related to patients treated by neoadjuvant
chemotherapy comprised 19 of the 23 breast cancer tri-
als. Immunohistochemistry (IHC) techniques were used
in all the trials to detect the expression of Bcl-2 protein.
Various antibodies were used to assess Bcl-2 expression,
and the cutoff in the number of positive cells defining a
tumor with Bcl-2 overexpression varies from 5% to 50%,
more than 10% for most studies (Table 1).
Evidence synthesis
Among the studies dealing with breast cancer patients
with chemotherapy response, twenty-three studies involv-
ing 2,467 patients contributed to data on total OR (clinical
OR + pathological OR). Negative Bcl-2 expression was sig-
nificantly associated with improved total OR among pa-
tients with chemotherapy (RR = 1.16; 95% CI = 1.02–1.32;
p = 0.026, Figure 2). Twelve studies involving 1,602 patients
contributed to data on CR (pathological CR + clinical CR).
Negative Bcl-2 expression was significantly associated with
improved CR (RR = 1.67; 95% CI = 1.24–2.24; p = 0.001).
Ten studies involving 1,285 patients contributed to data on
total pathological CR. In fact, all these patients received
neoadjuvant chemotherapy. Negative Bcl-2 expression was
significantly associated with improved pathological CR
(RR = 1.92; 95% CI = 1.38–2.69; p < 0.001).n and response to chemotherapy
Heterogeneity
RR (95% CI) P I2 (%) Ph
1.16(1.02–1.32) 0.026* 11.6 0.502
,31] 1.67(1.24–2.24) 0.001* 15.8 0.289
1.92(1.38–2.69) <0.001* 10.9 0.342
4] 1.19(1.04–1.37) 0.014* 17.7 0.234
,31] 1.67(1.24–2.24) 0.001* 15.8 0.289
1.92(1.38–2.69) <0.001* 10.9 0.342
1.20(1.01–1.43) 0.034* 15.5 0.280
] 1.76(1.24-2.51) 0.002* 0.0 0.452
1.37(0.88–2.14) 0.160# 46.3 0.071
2.11(1.14–3.88) 0.017* 0.0 0.525
ethod) according to the heterogeneity.
d Laird method) according to the heterogeneity.
group.
Figure 3 Forest plots of RR were assessed for association between Bcl-2 and pathological CR among breast cancer patients treated
with neoadjuvant therapy.
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Among the 23 studies, nineteen used neoadjuvant chemo-
therapy, one used first-line chemotherapy, one involving
neoadjuvant and first-line chemotherapies, and one failed
to report, we therefore calculated the associations with fa-
vorable responses to neoadjuvant chemotherapy. The re-
sults of subgroup analysis were presented in Table 2.
Negative Bcl-2 expression was significantly associated with
increased total OR (RR = 1.19, 95% CI = 1.04–1.37, p =
0.014), CR (RR = 1.67; 95% CI = 1.24–2.24; p = 0.001),
pathological CR (RR = 1.92; 95% CI = 1.38–2.69; p < 0.001,
Figure 3) among patients treated with neoadjuvant
chemotherapy.
Bcl-2 expression has been used to evaluate associations
with favorable responses to different treatment regimens
of chemotherapy(either by anthracycline- or taxane-
based). Among the 23 studies in the chemotherapy sub-
group, fifteen used anthracycline-based neoadjuvant
chemotherapy and eight used taxane-based neoadjuvant
chemotherapy, while five used both anthracyclines and
taxanes (Table 2). The results of the anthracycline- and
taxane-based neoadjuvant chemotherapies were therefore
calculated separately. No study contributed to data onclinical CR in the subgroup analysis. Negative Bcl-2 ex-
pression was associated with improved chemo-response in
breast cancer patients who received anthracycline-based
therapy (total OR: RR = 1.28, 95% CI = 1.01–1.43, p = 0.034,
Figure 4; pathological CR: RR = 1.76, 95% CI = 1.24–2.51,
p = 0.002). Negative Bcl-2 expression was significantly asso-
ciated with increased pathological CR (RR = 2.11; 95% CI =
1.14–3.88; p = 0.017) among patients treated with taxane-
based therapy, but not with total OR (RR = 1.37; 95%
CI =0.88–2.14; p = 0.160).Publication bias
Begg’s funnel plot and Egger’s test were used to estimate
the publication bias of the included literatures. The shapes
of the funnel plots showed no evidence of obvious asym-
metry (Figures 5 and 6), and Egger’s test indicated the ab-
sence of publication bias (p > 0.05). Moreover, sensitivity
analysis was carried out to assess the influence of individ-
ual study on the summary effects. No individual study
dominated this meta-analysis, and the removal of any sin-
gle study had no significant effect on the overall conclu-
sion (data not shown).
Figure 4 Forest plots of RR were assessed for the evaluation of total OR in anthracycline-based settings.
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Although there have been many attempts to correlate Bcl-
2 status with chemosensitivity in breast cancer patients,
the results have been controversial. Our systematic review
of the literatures shows that negative Bcl-2 expression is a
good prognostic factor for predicting sensitivity to chemo-
therapy of breast cancers. The analysis reveals similar fea-
tures in different subgroups and clarifies the message of
individual studies that are somewhat inconsistent.
In our systematic review with meta-analysis, patients
with Bcl-2-negative tumors had significantly better re-
sponse to chemotherapy than those with Bcl-2-positive
tumors. This observation is potentially important. The
identification of independent predictive factor allows us
to define high-risk patients for whom specific therapy
may be designed or to introduce stratification in ran-
domized trials. Furthermore, identifying and validating a
predictive biomarker is of more than purely scientific
interest because clinical Bcl-2 inhibition is now a prac-
ticable clinical approach. Recently, Abbott Laboratories
has two drugs in clinical trials that directly target Bcl-2,
ABT-263, and ABT-199 [35-37].Interestingly, we noticed that patients with Bcl-2-
negative tumors were more likely to achieve a complete
remission after neoadjuvant chemotherapy. Multiple
clinical trials have shown that patients who achieved a
pathological CR after neoadjuvant chemotherapy were
associated with improved survival. Intensive researches
have thus been focused on identification of “predictive
markers” of chemotherapy sensitivity, especially those
producing pathological CR [38]. Our results indicated
that Bcl-2 expression could potentially help to stratify
patients in neoadjuvant chemotherapy.
Notably, we found the correlation between Bcl-2
expression and the response to anthracycline-based
chemotherapy. It is important to mention that Vo TT
et al. found that Bcl-2 MOLM13 partial knockdown
was associated with increased death by topoisomer-
ase II inhibitors (etoposide, daunorubicin, and mitox-
antrone) in proportion to the quality of the
knockdown [7].
A combination of the analysis of Bcl-2 expression and
perhaps other variables (e.g., HER-2, hormone receptor,
tumor size and histological subtype) may make it
Figure 5 The funnel plot shows that there was no obvious indication of publication bias for the outcome of total OR.
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patients with advanced breast cancer.
The decision to perform the meta-analysis was based on
a prior methodological assessment of the publications. We
have used a methodology similar to previous systematic
reviews reported by our group on the treatment of breast
cancer [8] and rectal cancer after an adaptation to bio-
logical predictive factors such as p53 [39]. By comparing
the scores of the studies where Bcl-2 was a significantFigure 6 The funnel plot shows that there was no obvious indication
breast cancer patients treated with neoadjuvant therapy.predictive factor and those where it was not, we could iden-
tify differences, suggesting biases induced by trial method-
ology. Nevertheless, our approach does not eliminate all
potential biases. First, the meta-analysis may have been in-
fluenced by publication bias, we limited the search to stud-
ies written in English, and we did not search conference
proceedings and abstract books, which may have intro-
duced publication bias to this meta-analysis. We tried
to identify all relevant data and retrieve additionalof publication bias for the outcome of pathological CR among
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unavoidable. Second, the techniques used to identify over-
expression of Bcl-2 status can also be a potential source of
bias. The IHC used to reveal the Bcl-2 protein is not always
performed with the same antibody. Moreover, the cutoff in
the number of positive cells defining a tumour with Bcl-2
overexpression often varies according to the investigators,
which may lead to biased conclusions. Third, although we
made considerable efforts to standardize definitions, some
variability in definitions of methods, measurements, and
outcomes among studies was inevitable . Fourth, our ana-
lysis was observational in nature, and we therefore can’t
exclude confounding as a potential explanation of the ob-
served results. Despite these limitations, this meta-analysis
had several strengths. First, a substantial number of cases
were pooled from different studies, and 2,467 subjects rep-
resents a sizeable number to significantly increase the stat-
istical power of the analysis. Secondly, no publication biases
were detected, indicating that the pooled results may be
unbiased.
This study is the first meta-analysis to assess the use of
Bcl-2 expression for predicting the chemo-sensitivity of
breast cancer patients. Our data support Bcl-2 expression
as a useful predictive factor for assessing treatment re-
sponse to chemotherapy in breast cancer patients. How-
ever, future properly designed prospective studies with
large sample sizes and an appropriate statistical method-
ology including multivariate analysis are required to con-
firm our findings. Moreover, the interaction of this marker
with other markers such as HER-2, hormone receptor,
tumor size and histological subtype remains unknown and
should be a matter for further investigation.
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